- Home
- / TransCode Therapeutics
TransCode Therapeutics
Stock Price
$0.6
2024-10-29
Market Capitalization
$9.7 M
2024-10-29
TransCode Therapeutics Summary
Company Summary
- Overview
- TransCode Therapeutics is an RNA oncology company. Its therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Boston, MA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
LocationsView all
2 locations detected
Boston, MA HQ
United States
6 Liberty Square #2382
Worcester, MA
United States
17 Briden St
TransCode Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($17.8M)
- Cash (Q1, 2026)
- $12.8M
- EBIT (Q1, 2026)
- ($17.8M)